What is SciBac?
SciBac is at the forefront of biopharmaceutical innovation, utilizing a proprietary platform technology to engineer novel live biotherapeutics. Their approach involves mating beneficial microbes to create hybrid strains with meticulously selected traits designed to target diseases through multiple modes of action. The company's expanding pipeline includes promising treatments for conditions such as Clostridium difficile infections and chronic Pseudomonas infections in cystic fibrosis patients. This focus on antibiotic resistance and microbiome health positions SciBac as a key player in addressing critical unmet medical needs.
How much funding has SciBac raised?
SciBac has raised a total of $112K across 1 funding round:
Debt
$112K
Debt (2021): $112K with participation from PPP
What's next for SciBac?
With the recent influx of $112K in strategic investment, SciBac is well-positioned for accelerated growth and market penetration. This substantial capital infusion is expected to fuel the advancement of its pipeline, potentially enabling the company to move towards late-stage clinical trials and commercialization. The company's focus on antibiotic-resistant diseases, a growing global health concern, suggests a strategic direction aimed at capturing significant market share. Future developments will likely involve expanding manufacturing capabilities and forging strategic partnerships to broaden the reach of their rEvolutionary biotherapeutics.
See full SciBac company page
